# US 2023/0056424 A1 · Prevention of the conversion of pharmaceutical agents into toxic n-nitrosamine compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056424 A1
- Document ID: US20230056424A1
- Status: Published application
- Kind: A1
- Application number: 17/866,382
- Filed: 2022-07-15
- Published: 2023-02-23
- Earliest claimed: 2021-11-05
- Assignees: Alfred E. Tiefenbacher (GmbH & Co. KG)
- Applicants: Alfred E. Tiefenbacher (GmbH & Co. KG)
- Inventors: Alexander DÖBBER; Manohar Reddy SAGILI; Chaitanya Yogananda GUJJAR; Venkatasimhadri Naidu KALAMATA; Ansgar FITZNER; Santhosh Kumar MANKALA; Bala Ramesha Chary RALLABANDI; Kiran Kumar MADALLAPALLI
- Web page: https://patentgrep.com/patent/US20230056424A1

## CPC

- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/2095: {Tabletting processes}
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A pharmaceutical composition, which is an oral solid dosage form, containing a pharmaceutical agent comprising a dialkylamino- or a trialkylamino-group and one or more pharmaceutically acceptable excipient(s), wherein over a period of 2 weeks at 60° C. under open exposure (at any humidity between 30 and 75% rH), or 6 months at 40° C./75% rH in the primary packaging, or 6 months at 25° C./60% rH in the primary packaging the concentration of the corresponding N-nitroso-derivative of the pharmaceutical agent remains below 50 ppm (relative to the weight of the free base of the pharmaceutical agent in the pharmaceutical composition).

## Claims

### Claim 1

A pharmaceutical composition, which is an oral solid dosage form, containing a pharmaceutical agent comprising a dialkylamino- or a trialkylamino-group and one or more pharmaceutically acceptable excipient(s),
wherein over a period of
2 weeks at 60° C. under open exposure at any humidity between 30 and 75% rH, or
6 months at 40° C./75% rH in a primary packaging, or
6 months at 25° C./60% rH in a primary packaging,
the concentration of the corresponding N-nitroso-derivative of the pharmaceutical agent remains below 50 ppm, (relative to the weight of the free base of the pharmaceutical agent in the pharmaceutical composition).

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1 packed with a primary packaging, wherein over a period of
2 weeks at 60° C. under open exposure of the pharmaceutical composition as such at any humidity between 30 and 75% rH, or
6 months at 40° C./75% rH in the primary packaging, or
6 months at 25° C./60% rH in the primary packaging,
the concentration of the corresponding N-nitroso-derivative of the pharmaceutical agent remains below 50 ppm, (relative to the weight of the free base of the pharmaceutical agent in the pharmaceutical composition).

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein none of the alkyl-substituents of the dialkylamino- or the trialkylamino-group is an alkyl-group with the alpha-position being a tertiary carbon atom.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical agent is varenicline or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the pharmaceutically acceptable salt of varenicline is the tartrate or the citrate.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the solid dosage form is a tablet, capsule, pellets or granules, preferably a tablet.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition comprises an antioxidant.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, wherein the antioxidant is alpha-tocopherol, ascorbic palmitate, butylated hydroxyanisol, butylated hydroxytoluene, erythorbic acid, Vitamin E polyethylene glycol succinate, methionine, potassium metabisulfite, sodium metabisulfite, sodium ascorbate, sodium bisulfite, sodium formaldehyde sulfoxylate, or sodium sulfite, sodium thiosulfate, ascorbic acid or a salt thereof, or propyl gallate or a mixture thereof.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the antioxidant is propyl gallate in a concentration of 0.25-1.75 w.-%, (relative to the weight of the entire pharmaceutical composition).

### Claim 10 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition further comprises an organic acid.

### Claim 11 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the primary packaging is a pharmaceutically acceptable bottle optionally including any desiccant, or a pharmaceutically acceptable blister.

### Claim 12 (depends on 1)

A process for the manufacture of a pharmaceutical composition according to claim 1, wherein (a) pharmaceutically acceptable excipient(s) and/or a binder are wet granulated with an aqueous dispersion of an antioxidant so that wet granules are formed, (b) after drying said wet granules, the resulting dried granules are blended with the pharmaceutical agent and optionally another pharmaceutically acceptable excipient and/or an organic acid, and (c) optionally the resulting blend is dry granulated.

### Claim 13 (depends on 12)

The process according to claim 12, wherein the blend obtained in step (b) is dry granulated in step (c) and subsequently is either
(i) compressed to a tablet, typically together with a non-granular pharmaceutically acceptable excipient, or
(ii) filled into capsules.

### Claim 14 (depends on 12)

The process according to claim 12, wherein the aqueous dispersion also comprises a pharmaceutically acceptable alcohol.

### Claim 15 (depends on 12)

The process according to claim 12, wherein the aqueous dispersion also comprises an organic acid.

### Claim 16 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition is obtained by (a) wet granulating any pharmaceutically acceptable excipient(s) and/or a binder with an aqueous dispersion of an antioxidant so that wet granules are formed, (b) after drying said wet granules, the resulting dried granules are blended with the pharmaceutical agent and optionally another pharmaceutically acceptable excipient and/or an organic acid, and (c) dry granulating the resulting blend.

### Claim 17 (depends on 16)

The pharmaceutical composition according to claim 16, wherein (d) subsequently
(i) a tablet is obtained by compressing the dry granulated blend, optionally with a non-granular pharmaceutically acceptable excipient, or
(ii) capsules are obtained by filling the corresponding capsule shells with said dry granulated blend.

### Claim 18 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the concentration of the corresponding N-nitroso-derivative of the pharmaceutical agent remains below 30 ppm, below 18.5 ppm, below 10 ppm, below 5 ppm below 2 ppm, or below 1 ppm.

### Claim 19 (depends on 7)

The pharmaceutical composition according to claim 7, wherein the antioxidant is in a concentration of at least 0.1 w.-%, or at least 0.25 w.-% (relative to the weight of the entire pharmaceutical composition).

### Claim 20 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the organic acid is citric acid or tartaric acid.
